Bentiromide
From Wikipedia, the free encyclopedia
 |
|
|
Bentiromide
|
|
| Systematic (IUPAC) name | |
| 4-[2-benzamido-3- (4-hydroxyphenyl)- propanoyl] aminobenzoic acid | |
| Identifiers | |
| CAS number | 37106-97-1 |
| ATC code | V04CK03 |
| PubChem | 2329 |
| DrugBank | APRD00818 |
| Chemical data | |
| Formula | C23H20N2O5 |
| Mol. weight | 404.415 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Bentiromide is a peptide used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy. It is given by mouth as a noninvasive test. The amount of 4-aminobenzoic acid and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas. Headache and gastrointestinal disturbances have been reported in patients taking bentiromide. Bentiromide is not available in the U.S. or Canada (It was withdrawn in the US in October 1996.)
[edit] See also
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
